US2022177568A1PendingUtilityA1

Treatment of skin lesions and pruritus in prurigo nodularis patients

49
Assignee: Galderma Holding SAPriority: Jan 28, 2019Filed: Dec 20, 2021Published: Jun 9, 2022
Est. expiryJan 28, 2039(~12.5 yrs left)· nominal 20-yr term from priority
Inventors:Christophe Piketty
A61K 39/3955A61K 2039/54A61K 2039/505A61K 9/0029A61K 2039/545A61P 17/04C07K 16/2866C07K 16/244A61K 9/0014
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are methods for selectively treating pruritus in a subject having chronic prurigo (CP), including prurigo nodularis (PN), pharmaceutical compositions for use in the treatment of pruritus in a subject having CP or PN, uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of pruritus in a subject having CP or PN.

Claims

exact text as granted — not AI-modified
1 .- 29 . (canceled) 
     
     
         30 . A method of treating skin lesions and pruritus in a subject having chronic prurigo (CP), comprising administering about 30 mg to about 60 mg of nemolizumab or an equivalent thereof to the subject. 
     
     
         31 . The method of  claim 30 , wherein the subject has prurigo nodularis (PN). 
     
     
         32 . The method of  claim 31 , wherein the subject has been diagnosed of PN for at least about 6 months. 
     
     
         33 . The method of  claim 30 , wherein the subject has at least about 20 nodules on his/her body with a bilateral distribution. 
     
     
         34 . The method of  claim 30 , wherein the subject has prurigo lesions on upper limbs. 
     
     
         35 . The method of  claim 30 , wherein the pruritus has been assigned a score of at least 4 on the Numerical Rating Scale (NRS). 
     
     
         36 . The method of  claim 30 , wherein the pruritus has been assigned a score of at least 7 on the Numerical Rating Scale (NRS). 
     
     
         37 . The method of  claim 30 , wherein the subject does not have atopic dermatitis. 
     
     
         38 . The method of  claim 30 , wherein the nemolizumab or the equivalent thereof is administered to the subject according to a flat dosing regimen. 
     
     
         39 . The method of  claim 30 , wherein the nemolizumab or the equivalent thereof is administered to the subject according to a loading dose regimen. 
     
     
         40 . The method of  claim 30 , wherein 30 mg or 60 mg of nemolizumab or the equivalent thereof is administered to the subject. 
     
     
         41 . The method of  claim 30 , wherein the nemolizumab or the equivalent thereof is administered to the subject once every four weeks. 
     
     
         42 . The method of  claim 30 , wherein the nemolizumab or the equivalent thereof is administered subcutaneously. 
     
     
         43 . A method of treating prurigo nodularis (PN), comprising subcutaneously administering about 30 mg to about 60 mg of nemolizumab to a subject with PN. 
     
     
         44 . The method of  claim 43 , wherein the subject has been diagnosed of PN for at least about 6 months. 
     
     
         45 . The method of  claim 43 , wherein the subject has at least about 20 nodules on his/her body with a bilateral distribution. 
     
     
         46 . The method of  claim 43 , wherein the subject has prurigo lesions on upper limbs. 
     
     
         47 . The method of  claim 43 , wherein the pruritus has been assigned a score of at least 4 on the Numerical Rating Scale (NRS). 
     
     
         48 . The method of  claim 43 , wherein the pruritus has been assigned a score of at least 7 on the Numerical Rating Scale (NRS). 
     
     
         49 . The method of  claim 43 , wherein the subject does not have atopic dermatitis. 
     
     
         50 . The method of  claim 43 , wherein the nemolizumab is administered to the subject according to a flat dosing regimen. 
     
     
         51 . The method of  claim 43 , wherein the nemolizumab is administered to the subject according to a loading dose regimen. 
     
     
         52 . The method of  claim 43 , wherein 30 mg or 60 mg of nemolizumab or the equivalent thereof is administered to the subject. 
     
     
         53 . The method of  claim 43 , wherein the nemolizumab or the equivalent thereof is administered to the subject once every four weeks. 
     
     
         53 . The method of  claim 43 , wherein 60 mg of nemolizumab is administered to the subject once every four weeks. 
     
     
         54 . The method of  claim 43 , wherein a first administration comprises 60 mg of nemolizumab and subsequent administrations comprise 30 mg of nemolizumab, wherein any subsequent administration is given once every four weeks.

Join the waitlist — get patent alerts

Track US2022177568A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.